Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Deciphering Circulating Signatures of Infected Pancreatic Necrosis

Project description

Diagnostic biomarkers for infected acute pancreatitis

Acute pancreatitis is a sudden inflammation of the pancreas, and in severe cases it may progress to necrosis of pancreatic tissue (necrotising pancreatitis) (NP). This can significantly increase the risk of complications including infection (infected pancreatic necrosis, IPN), which can lead to high morbidity and mortality rates. Current diagnostics cannot differentiate between NP and IPN which is crucial for better outcomes. Funded by the Marie Skłodowska-Curie Actions programme, the DECISION project aims to develop a list of biomarkers that can assist in the early diagnosis of IPN. Using machine learning, the project will select a combination of biormakers and validate them in a clinical trial, contributing to the clinical management of patients worldwide

Objective

Acute pancreatitis is a common disease that can progress to gland necrosis (necrotizing pancreatitis [NP]). NP imposes significant risk of morbidity, mortality, and substantial healthcare costs, especially when infected (infected pancreatic necrosis [IPN)]. A preemptive approach with early IPN recognition is suggested to improve patient outcomes. However, existing diagnostic tools fail to distinguish IPN from sterile NP early in the disease course. Furthermore, related studies on potential serum markers lack sufficient methods of assessment. The aim of this project is to develop a simple, reliable, and cost-effective biomarker panel for accelerated and improved decision-making, validated on real patient results. First, we use information theory and machine learning to select the best-performing combination of available serum cytokines for detecting IPN. The accuracy and prediction abilities of the biomarker panel are then verified in an independent cohort using the standardized prospective specimen collection, retrospective blinded evaluation study design for pivotal evaluation of biomarkers. Finally, the net benefit to patients and costs by incorporating effects of clinical decisions based on the panel is assessed through a multicenter randomized controlled trial. The project creates a critical step in the improvement of care and clinical management in millions of patients worldwide. Moreover, the systematic phased approach facilitates open science and reproducibility. As the panel moves from research to application, it offers potential for commercial exploitation. In the longer term, if clinically validated, the test can be adopted by the larger clinical community for further research and more personalized care.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

UNIVERZITA PALACKEHO V OLOMOUCI
Net EU contribution
€ 319 273,20
Address
KRIZKOVSKEHO 8
771 47 Olomouc
Czechia
Region
Česko Střední Morava Olomoucký kraj
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (2)